Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire...
Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapiesCREXONT delivered substantial “Off” time reductions,...
Major Regulatory Milestone: The first Canadian-developed AI for ICH triage receives FDA clearance to enter the U.S. market.Operational Value: Automates...
LOUISVILLE, Ky., Dec. 4, 2025 /PRNewswire/ -- Sir Simon Baron-Cohen has received the 2026 Grawemeyer Award in Psychology, a distinction...
Preliminary results indicate HHT patients are significantly impacted by bleeding events, with consistency in severity reporting at months one and...
First video-documented ALS reversal marks a new era for brain health achieved through noninvasive computerized brain-temperature modulation, confirmed by electrophysiological,...
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of...
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of...
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical")...
MIDDLETON, Wis., Dec. 3, 2025 /PRNewswire/ -- Natus Medical Incorporated announced the electrographic status epilepticus diagnosis capability of its BrainWatch point-of-care...
New policy recognizes the Nerivio REN wearable as medically necessary for both acute and preventive treatment of migraine in patients...
Study in Lancet Digital Health represents the largest real-world evaluation of stroke AI imaging, encompassing data from more than 450,000...
FORT MYERS, Fla., Dec. 2, 2025 /PRNewswire/ -- Bridge To A Cure Foundation announces the appointment of Winston Ely to its...
Expert in sales and commercial strategy…Ex-Philips and previously served as Chief Commercial Officer (CCO) at Cortechs.aiTo strengthen revenue growth of...
Los Angeles, California--(Newsfile Corp. - December 2, 2025) - This Giving Tuesday the St. Baldrick's Foundation, the largest charity funder...
The multi-year partnership launches with focus on epilepsy, rare disease and AISAN FRANCISCO and ATLANTA, Dec. 02, 2025 (GLOBE NEWSWIRE)...
NEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic...
HOUSTON, TX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL) is pleased to...
Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF penetration in healthy elderly...
December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals...